Literature DB >> 12921122

Peptide based adsorbers for therapeutic immunoadsorption.

Wolfgang Rönspeck1, Roland Brinckmann, Ralf Egner, Frank Gebauer, Dirk Winkler, Petra Jekow, Gerd Wallukat, Johannes Müller, Rudolf Kunze.   

Abstract

Peptides as ligands for immunoadsorption exhibit several potential advantages over native proteins. Two newly developed adsorbers are based on peptides covalently coupled to sepharose CL-4B. Globaffin is capable of binding immunoglobulins independent from their antigen specificity and thus, applicable in transplant recipients and several antibody mediated autoimmune diseases. Among others, the most important disorders suitable for the treatment with Globaffin are rheumatoid arthritis, systemic lupus erythematosus, and acute renal transplant rejection. Coraffin is a specific adsorber using two linear peptide ligands mimicking epitopes of the beta1-adrenergic receptor, that bind corresponding autoantibodies from patients suffering from idiopathic dilated cardiomyopathy. Specific immunoadsorption has been shown to be beneficial for patients with dilated cardiomyopathy. Coraffin can be used as a new therapeutic option for these patients, who get only limited benefit from medical therapy. Both adsorbers may be combined with all approved apheresis control devices available.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12921122     DOI: 10.1046/j.1526-0968.2003.00017.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  10 in total

Review 1.  Maternal Anti-Fetal Brain IgG Autoantibodies and Autism Spectrum Disorder: Current Knowledge and its Implications for Potential Therapeutics.

Authors:  Elizabeth Fox-Edmiston; Judy Van de Water
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

2.  Anti-beta1-adrenergic receptor autoantibodies in patients with chronic Chagas heart disease.

Authors:  V Labovsky; C R Smulski; K Gómez; G Levy; M J Levin
Journal:  Clin Exp Immunol       Date:  2007-04-05       Impact factor: 4.330

3.  Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications.

Authors:  Kornelius Fuchs; Silke Rummler; Wolfgang Ries; Matthias Helmschrott; Jochen Selbach; Friedlinde Ernst; Christian Morath; Adelheid Gauly; Saynab Atiye; Manuela Stauss-Grabo; Mareike Giefer
Journal:  Ther Apher Dial       Date:  2021-05-06       Impact factor: 2.195

Review 4.  The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid.

Authors:  Kelly N Messingham; Tyler P Crowe; Janet A Fairley
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

5.  Successful treatment of severe interstitial pneumonia by removal of circulating autoantibodies: a case series.

Authors:  Philipp Eller; Holger Flick; Gernot Schilcher; Florentine Moazedi-Fürst; Kathrin Eller; Emina Talakic; Josef Hermann; Yannick Allanore; Horst Olschewski
Journal:  BMC Pulm Med       Date:  2021-01-06       Impact factor: 3.317

6.  SARS-CoV-2 IgG spike protein antibody response in mRNA-1273 Moderna® vaccinated patients on maintenance immunoapheresis - a cohort study.

Authors:  Martina Gaggl; Constantin Aschauer; Christof Aigner; Gregor Bond; Andreas Vychytil; Robert Strassl; Ludwig Wagner; Gere Sunder-Plassmann; Alice Schmidt
Journal:  Front Immunol       Date:  2022-09-26       Impact factor: 8.786

7.  Impact of human autoantibodies on β1-adrenergic receptor conformation, activity, and internalization.

Authors:  Beatrice Bornholz; Stefanie Weidtkamp-Peters; Stephanie Schmitmeier; Claus A M Seidel; Lars R Herda; Stephan B Felix; Horst Lemoine; Jürgen Hescheler; Filomain Nguemo; Christoph Schäfer; Morten O Christensen; Christian Mielke; Fritz Boege
Journal:  Cardiovasc Res       Date:  2012-12-03       Impact factor: 10.787

8.  Agonistic Autoantibodies to the β2-Adrenergic Receptor Involved in the Pathogenesis of Open-Angle Glaucoma.

Authors:  Anselm Jünemann; Bettina Hohberger; Jürgen Rech; Ahmed Sheriff; Qin Fu; Ursula Schlötzer-Schrehardt; Reinhard Edmund Voll; Sabine Bartel; Hubert Kalbacher; Johan Hoebeke; Robert Rejdak; Folkert Horn; Gerd Wallukat; Rudolf Kunze; Martin Herrmann
Journal:  Front Immunol       Date:  2018-02-12       Impact factor: 7.561

Review 9.  Therapeutic apheresis in kidney transplantation: An updated review.

Authors:  Maurizio Salvadori; Aris Tsalouchos
Journal:  World J Transplant       Date:  2019-10-28

10.  Apheresis Efficacy and Tolerance in the Setting of HLA-Incompatible Kidney Transplantation.

Authors:  Johan Noble; Antoine Metzger; Hamza Naciri Bennani; Melanie Daligault; Dominique Masson; Florian Terrec; Farida Imerzoukene; Beatrice Bardy; Gaelle Fiard; Raphael Marlu; Eloi Chevallier; Benedicte Janbon; Paolo Malvezzi; Lionel Rostaing; Thomas Jouve
Journal:  J Clin Med       Date:  2021-03-23       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.